What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.

Abstract

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below). Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents. Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details)-post (with credit card details or cheque)-phone during office hours (credit card only). Additionally the HTA website allows you to either print out your order or download a blank order form. Tel: 0845 812 4000-ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001-put 'HTA Order' on the fax header Payment methods Paying by cheque If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit card You can order using your credit card by phone, fax or post. Subscriptions NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD? Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide. The website also provides information about the HTA programme and lists the membership of the various committees. HTA What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional ...

A feasibility randomised controlled trial of a motivational interviewing-based intervention for weight loss maintenance in adults

“…We intended to use trial data on utility measures and costs of interventions in the model and to obtain costs of obesity-related complications in the UK from the published literature. 130 As a generic measure, it was considered that EQ-5D may not be sufficiently sensitive to capture differences in health-related quality of life in these essentially healthy participants. A within-trial cost-effectiveness study was therefore also planned with BMI at 3 years as the effectiveness measure.…”

Association between body mass index and health-related quality of life, and the impact of self-reported long-term conditions – cross-sectional study from the south Yorkshire cohort dataset

“…Deviations away from the healthy weight range are associated with a lower health-related quality of life (HRQoL) [2][3][4].…”

Farmacoterapia da obesidade: Benefícios e Riscos

“…Considerando que a obesidade, nos dias atuais, é um problema de saúde pública mundial, pois vem crescendo em ritmo acelerado, segundo a Organização Mundial de Saúde (OMS) a projeção para 2015 seria de aproximadamente 2,3 bilhões de adultos com excesso de peso e mais de 700 milhões de obesos 44 , é interessante o conhecimento sobre a farmacoterapia da obesidade disponível atualmente no mercado farmacêutico brasileiro.…”